December 3rd, 2008
A new Canadian study links the diabetes drug Avandia to higher rates of death, heart attack, and congestive heart failure in diabetes patients aged 66 and older.
The researchers say their study is the first to document a higher death rate among patients taking thiazolidinediones a class of diabetes drugsthat includes ...
November 24th, 2008
Older diabetes patients treated with Takeda Pharmaceutical North American Inc.'s Actos and GlaxoSmithKline Plc.'s Avandia had a "significant" increased risk of heart attack, congestive heart failure and death compared to those taking an older treatment for people with diabetes, according to a study in this week's Journal of the American ...
November 19th, 2008
A Canadian study is adding to concerns about the safety of a class of drugs for Type 2 diabetes after at least one of the medications appeared to raise the risk of heart failure, heart attack and death in older patients.
The study by the Institute for Clinical Evaluative Sciences (ICES) ...
October 29th, 2008
A large pharmacy benefits administrator health Tran's pharmacy and therapeutics has removed Avandia from its value-based formulary effective January 1, 2009. This decision is another blow to Glaxo Smith Kline's once popular Avandia diabetes medication. Health strands made the decision after clinical data revealed that Avandia may be associated ...
July 1st, 2008
European and U.S. diabetologists called on Tuesday for greater caution in prescribing oral diabetes pills like GlaxoSmithKline Plc's Avandia, which has been linked to increased heart attack risk.
Glaxo's Avandia has lost ground to Takeda Pharmaceutical Co Ltd's Actos in recent months, following publication of a U.S. study in May criticizing ...
April 28th, 2008
Over a period of several years, drug maker GlaxoSmithKline PLC was so concerned about a prominent physician's negative views of its diabetes drug that it engaged in a concerted effort to intimidate him and stifle his opinion, a report by the U.S. Senate Finance Committee found.
The report offers a window ...
April 8th, 2008
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths ...
February 14th, 2008
The government slapped a prominent, though confusing, warning on the popular diabetes drug Avandia on Wednesday — telling patients that it may, or may not, increase the risk of heart attacks.
The move is less stringent than steps Canada took last week to restrict the drug's use to hard-to-treat diabetics.
But the ...
February 5th, 2008
The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.
People with type 2 diabetes who have ...
January 24th, 2008
The widely used diabetes drug Avandia got a new warning label Wednesday telling patients that it may, or may not, increase the risk of heart attacks.
Why the confusion? The Food and Drug Administration said studies of the risk are too contradictory to tell if Avandia really is riskier than other ...
